Provided by Tiger Trade Technology Pte. Ltd.

Neurosense Therapeutics Ltd

7.03
+0.13001.88%
Pre-market: 6.36-0.6700-9.53%08:31 EDT
Volume:42.31K
Turnover:286.02K
Market Cap:13.27M
PE:-0.81
High:7.29
Open:6.43
Low:6.06
Close:6.90
52wk High:26.64
52wk Low:5.00
Shares:1.89M
Float Shares:1.29M
Volume Ratio:1.45
T/O Rate:3.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.7319
EPS(LYR):-8.7319
ROE:-2174.98%
ROA:-247.30%
PB:-8.51
PE(LYR):-0.81

Loading ...

Neurosense Therapeutics - Expects to File Submission to Health Canada in Coming Months

THOMSON REUTERS
·
Jul 22

Neurosense Therapeutics Announces Press Release Availability

Reuters
·
Jul 22

Neurosense Plans Primec New Drug Filing with Health Canada for ALS

Reuters
·
Jul 22

Neurosense Therapeutics Ltd. (NRSN) Gets a Buy from Noble Financial

TIPRANKS
·
Jul 02

Neurosense Therapeutics Achieves Primary Endpoint in Phase 2B ALS Study

Reuters
·
Jun 29

Neurosense Rises as Nerve Disease Drug Shows Promise in Study

Reuters
·
Jun 29

NeuroSense says Phase 2b PARADIGM study of PrimeC in ALS met endpoint

TIPRANKS
·
Jun 29

Neurosense Says Phase 2b ALS Trial Meets Primary Endpoint, Cuts Tdp-43 vs Placebo (p=0.0421)

Reuters
·
Jun 29

Neurosense Achieves Primary Endpoint in Phase 2B ALS Study with Statistically Significant Reduction of Tdp-43, the Defining Pathological Hallmark of ALS

THOMSON REUTERS
·
Jun 29

Neurosense Therapeutics - Primec Shows Favorable Safety Profile with no New Safety Signals over 18 Months

THOMSON REUTERS
·
Jun 29

Neurosense Reports Positive Biomarker Findings from Phase 2 Road Proof-of-concept Study of Primec in Alzheimer's Disease

THOMSON REUTERS
·
Jun 25

NeuroSense joins EverythingALS community event on PrimeC data in ALS

Reuters
·
Jun 22

NeuroSense CEO Alon Ben-Noon acquires 250,000 shares worth USD 200,000

Reuters
·
Jun 18

Neurosense Therapeutics - Granted South Korean Patent Covering Primec Composition for ALS

THOMSON REUTERS
·
Jun 11

NeuroSense wins South Korean patent for PrimeC ALS drug composition through 2042

Reuters
·
Jun 11

Roth MKM Keeps Their Buy Rating on Neurosense Therapeutics Ltd. (NRSN)

TIPRANKS
·
Jun 10

NeuroSense secures Japan patent for PrimeC ALS drug formulation through 2042

Reuters
·
Jun 09

NeuroSense meets Health Canada on PrimeC regulatory pathway for ALS drug submission

Reuters
·
Jun 08

NeuroSense prices $600,000 private placement at $0.8 per share

Reuters
·
Apr 29

Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Eton Pharmaceuticals (ETON) and Ligand Pharma (LGND)

TIPRANKS
·
Apr 27